Lifeward Q3 revenue $6.2M (+1% YoY); net loss $0.20/shr; secures $3M loan from Oramed

Lifeward Ltd.

2025-Q3 EPS reported -$1.16 revenue$16,953,000

Revenue $6.2M (+1% YoY); traditional products up 24% to $3.1M; AlterG down 15% to $3.1M.
GAAP net loss $3.2M ($0.20/shr); non-GAAP net loss $3.0M ($0.19/shr) vs $4.0M ($0.45/shr) YoY.
Cash used in ops $3.8M (down from $4.5M YoY); unrestricted cash $2.0M at quarter end.
Entered $3.0M secured loan from Oramed at 15%, convertible at $0.45/shr, matures May 2026.
Reaffirmed FY2025 guidance: revenue $24-26M; non-GAAP net loss $12-14M.

item 1.01item 2.02item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.